Emil Laust Kristoffersen

Mr. Emil Laust Kristoffersen


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2013 in ACS Nano
Verified
Journal Article
Closed access
SJSissel Juul
Sissel Juul
Federico IacovelliFederico Iacovelli
Federico Iacovelli
Mattia FalconiMattia Falconi
Mattia Falconi
SKSofie L. Kragh
Sofie L. Kragh
BCBrian Christensen
Brian Christensen
BKBirgitta Knudsen
Birgitta Knudsen

2 November 2012 in ACS Nano
Verified
Journal Article
Closed access
SJSissel Juul
Sissel Juul
CNChristine J. F. Nielsen
Christine J. F. Nielsen
RLRodrigo Labouriau
Rodrigo Labouriau
ARAmit Roy
Amit Roy
CTCinzia Tesauro
Cinzia Tesauro
BKBirgitta Knudsen
Birgitta Knudsen

2 February 2022 in eLife
Verified
Journal Article
Open access
EKEmil Laust Kristoffersen
Emil Laust Kristoffersen
MBMatthew Burman
Matthew Burman
ANAgnes Noy
Agnes Noy
PHPhilipp Holliger
Philipp Holliger
RNA-catalyzed RNA replication is widely considered a key step in the emergence of life’s first genetic system. However, RNA replication can be impeded by the extraordinary stability of duplex RNA products, which must be dissociated for re-initiation of the next replication cycle. Here, we have explored rolling circle synthesis (RCS) as a potential solution to this strand separation problem. We observe sustained RCS by a triplet polymerase ribozyme beyond full-length circle synthesis with strand displacement yielding concatemeric RNA products. Furthermore, we show RCS of a circular Hammerhead ribozyme capable of self-cleavage and re-circularization. Thus, all steps of a viroid-like RNA replication pathway can be catalyzed by RNA alone. Finally, we explore potential RCS mechanisms by molecular dynamics simulations, which indicate a progressive build-up of conformational strain upon RCS with destabilization of nascent strand 5′- and 3′-ends. Our results have implications for the emergence of RNA replication and for understanding the potential of RNA to support complex genetic processes.

1 October 2013 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
PJPia W. Jensen
Pia W. Jensen
Mattia FalconiMattia Falconi
Mattia Falconi
EKEmil Laust Kristoffersen
Emil Laust Kristoffersen
ASAnita T. Simonsen
Anita T. Simonsen
JCJèssica B. Cifuentes
Jèssica B. Cifuentes
MSMagnus Stougaard
Magnus Stougaard

4 September 2025 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Open access
RKRachael C. Kretsch
Rachael C. Kretsch
RAReinhard Albrecht
Reinhard Albrecht
EAEbbe S. Andersen
Ebbe S. Andersen
HCHsuan‐Ai Chen
Hsuan‐Ai Chen
WCWah Chiu
Wah Chiu
AKAndriy Kryshtafovych
Andriy Kryshtafovych
Accurate biomolecular structure prediction enables the prediction of mutational effects, the speculation of function based on predicted structural homology, the analysis of ligand binding modes, experimental model building, and many other applications. Such algorithms to predict essential functional and structural features remain out of reach for biomolecular complexes containing nucleic acids. Here, we report a quantitative and qualitative evaluation of nucleic acid structures for the CASP16 blind prediction challenge by 12 of the experimental groups who provided nucleic acid targets. Blind predictions accurately model secondary structure and some aspects of tertiary structure, including reasonable global folds for some complex RNAs; however, predictions often lack accuracy in the regions of highest functional importance. All models have inaccuracies in non‐canonical regions where, for example, the nucleic‐acid backbone bends, deviating from an A‐form helix geometry, or a base forms a non‐standard hydrogen bond (not a Watson‐Crick base pair). These bends and non‐canonical interactions are integral to forming functionally important regions such as RNA enzymatic active sites. Additionally, the modeling of conserved and functional interfaces between nucleic acids and ligands, proteins, or other nucleic acids remains poor. For some targets, the experimental structures may not represent the only structure the biomolecular complex occupies in solution or in its functional life cycle, posing a future challenge for the community.

1 May 2015 in Nanoscale
Verified
Journal Article
Closed access
PDF file
EKEmil Laust Kristoffersen
Emil Laust Kristoffersen
LJLine A. Jørgensen
Line A. Jørgensen
OFOskar Franch
Oskar Franch
MEMichael Etzerodt
Michael Etzerodt
RFRikke Frøhlich
Rikke Frøhlich
BKBirgitta Knudsen
Birgitta Knudsen
Human DNA topoisomerase I (hTopI) is a nuclear enzyme that catalyzes relaxation of super helical tension that arises in the genome during essential DNA metabolic processes. This is accomplished through a common reaction mechanism shared among the type IB topoisomerase enzymes, including eukaryotic and poxvirus topoisomerase I. The mechanism of hTopI is specifically targeted in cancer treatment using camptothecin derivatives. These drugs convert the hTopI activity into a cellular poison, and hence the cytotoxic effects of camptothecin derivatives correlate with the hTopI activity. Therefore, fast and reliable techniques for high throughput measurements of hTopI activity are of high clinical interest. Here we demonstrate potential applications of a fluorophore-quencher based DNA sensor designed for measurement of hTopI cleavage-ligation activities, which are the catalytic steps affected by camptothecin. The kinetic analysis of the hTopI reaction with the DNA sensor exhibits a characteristic burst profile. This is the result of a two-step ping-pong reaction mechanism, where a fast first reaction, the one creating the signal, is followed by a slower second reaction necessary for completion of the catalytic cycle. Hence, the burst profile holds information about two reactions in the enzymatic mechanism. Moreover, it allows the amount of active enzyme in the reaction to be determined. The presented results pave the way for future high throughput drug screening and the potential of measuring active hTopI concentrations in clinical samples for individualized treatment.